Limits...
Cucurbitacin E induces cell cycle G2/M phase arrest and apoptosis in triple negative breast cancer.

Kong Y, Chen J, Zhou Z, Xia H, Qiu MH, Chen C - PLoS ONE (2014)

Bottom Line: In this study, we compared the effects of 12 phytochemical drugs on four cancer cell lines, and noticed that Cucurbitacin E (CuE) significantly inhibited TNBC cell growth by inducing cell cycle G2/M phase arrest and apoptosis.CuE reduced expression of Cyclin D1, Survivin, XIAP, Bcl2, and Mcl-1 in MDA-MB-468 and SW527, and within MDA-MB-468, CuE significantly increased activation of JNK and inhibited activation of AKT and ERK.Collectively, these results suggest that CuE may be a viable compound for developing novel TNBC therapeutics.

View Article: PubMed Central - PubMed

Affiliation: Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China; Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, Yunnan, China.

ABSTRACT
Triple negative breast cancer (TNBC) is a highly aggressive form of breast cancer resistant to many common treatments. In this study, we compared the effects of 12 phytochemical drugs on four cancer cell lines, and noticed that Cucurbitacin E (CuE) significantly inhibited TNBC cell growth by inducing cell cycle G2/M phase arrest and apoptosis. CuE reduced expression of Cyclin D1, Survivin, XIAP, Bcl2, and Mcl-1 in MDA-MB-468 and SW527, and within MDA-MB-468, CuE significantly increased activation of JNK and inhibited activation of AKT and ERK. Collectively, these results suggest that CuE may be a viable compound for developing novel TNBC therapeutics.

Show MeSH

Related in: MedlinePlus

CuE suppresses DNA synthesis in MDA-MB-468 and SW527 TNBC cell lines.A. CuE (0–50–100–200 nM) was used to treat MDA-MB-468 and SW527 cells for 24 h. DNA synthesis was measured by the EdU assay. B. Quantitative data of MDA-MB-468. Percentage of EdU positive proliferating cells vs. total cells is shown. *** p<0.001, student t-test. C. Quantitative data of SW527. Percentage of EdU positive proliferating cells vs. total cells is shown. ** p<0.01, *** p<0.001, student t-test.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4114842&req=5

pone-0103760-g002: CuE suppresses DNA synthesis in MDA-MB-468 and SW527 TNBC cell lines.A. CuE (0–50–100–200 nM) was used to treat MDA-MB-468 and SW527 cells for 24 h. DNA synthesis was measured by the EdU assay. B. Quantitative data of MDA-MB-468. Percentage of EdU positive proliferating cells vs. total cells is shown. *** p<0.001, student t-test. C. Quantitative data of SW527. Percentage of EdU positive proliferating cells vs. total cells is shown. ** p<0.01, *** p<0.001, student t-test.

Mentions: To investigate whether CuE inhibits cell proliferation in TNBC cell lines, we used an EdU assay to measure the DNA synthesis [12]. Results showed that CuE dramatically inhibited DNA synthesis in both MDA-MB-468 and SW527 cell lines in a dosage dependent manner (Fig. 2).


Cucurbitacin E induces cell cycle G2/M phase arrest and apoptosis in triple negative breast cancer.

Kong Y, Chen J, Zhou Z, Xia H, Qiu MH, Chen C - PLoS ONE (2014)

CuE suppresses DNA synthesis in MDA-MB-468 and SW527 TNBC cell lines.A. CuE (0–50–100–200 nM) was used to treat MDA-MB-468 and SW527 cells for 24 h. DNA synthesis was measured by the EdU assay. B. Quantitative data of MDA-MB-468. Percentage of EdU positive proliferating cells vs. total cells is shown. *** p<0.001, student t-test. C. Quantitative data of SW527. Percentage of EdU positive proliferating cells vs. total cells is shown. ** p<0.01, *** p<0.001, student t-test.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4114842&req=5

pone-0103760-g002: CuE suppresses DNA synthesis in MDA-MB-468 and SW527 TNBC cell lines.A. CuE (0–50–100–200 nM) was used to treat MDA-MB-468 and SW527 cells for 24 h. DNA synthesis was measured by the EdU assay. B. Quantitative data of MDA-MB-468. Percentage of EdU positive proliferating cells vs. total cells is shown. *** p<0.001, student t-test. C. Quantitative data of SW527. Percentage of EdU positive proliferating cells vs. total cells is shown. ** p<0.01, *** p<0.001, student t-test.
Mentions: To investigate whether CuE inhibits cell proliferation in TNBC cell lines, we used an EdU assay to measure the DNA synthesis [12]. Results showed that CuE dramatically inhibited DNA synthesis in both MDA-MB-468 and SW527 cell lines in a dosage dependent manner (Fig. 2).

Bottom Line: In this study, we compared the effects of 12 phytochemical drugs on four cancer cell lines, and noticed that Cucurbitacin E (CuE) significantly inhibited TNBC cell growth by inducing cell cycle G2/M phase arrest and apoptosis.CuE reduced expression of Cyclin D1, Survivin, XIAP, Bcl2, and Mcl-1 in MDA-MB-468 and SW527, and within MDA-MB-468, CuE significantly increased activation of JNK and inhibited activation of AKT and ERK.Collectively, these results suggest that CuE may be a viable compound for developing novel TNBC therapeutics.

View Article: PubMed Central - PubMed

Affiliation: Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China; Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, Yunnan, China.

ABSTRACT
Triple negative breast cancer (TNBC) is a highly aggressive form of breast cancer resistant to many common treatments. In this study, we compared the effects of 12 phytochemical drugs on four cancer cell lines, and noticed that Cucurbitacin E (CuE) significantly inhibited TNBC cell growth by inducing cell cycle G2/M phase arrest and apoptosis. CuE reduced expression of Cyclin D1, Survivin, XIAP, Bcl2, and Mcl-1 in MDA-MB-468 and SW527, and within MDA-MB-468, CuE significantly increased activation of JNK and inhibited activation of AKT and ERK. Collectively, these results suggest that CuE may be a viable compound for developing novel TNBC therapeutics.

Show MeSH
Related in: MedlinePlus